1. American Psychiatric Association (1987) Diagnostic and statistical manual of mental disorders. American Psychiatric Association, Washington
2. Blessed G, Tomlinson BE, Roth M (1968) The association between quantitative measures of dementia and of senile dementia in the cerebral grey matter of elderly subjects. Br J Psychiatry 114:791–811
3. Crawford JR, Besson JAO, Evans NTS, Roeda D, Kulkarni V, Parker DM, Ebmeier KP, Allan KM, Mallard JR (1991a) Cerebral blood flow in Alzheimer's disease imaged by positron emission tomography: the effects of physostigmine infusion. In: Kalousek M (ed) Janssen Symposium 17 Geronto-Psychiatrie. Janssen, Neuss (in press)
4. Crawford JR, Besson JAO, Ebmeier KP (1991b) Dementia: the role of neurotransmitter deficits. In: Dinan TG (ed) Principles and practice of biological psychiatry. Clinical Neuroscience, London, pp 105–134
5. Cutler NR, Murphy MF, Nash RJ, Prior PL, De Luna DM (1990) Clinical safety, tolerance, and plasma levels of the oral anti-cholinesterase 1,2,3,4-tetrahydro-9-aminoacridin-1-ol-maleate (HP 029) in Alzheimer's disease: preliminary findings. J Clin Pharmacol 30:556–561